Intelligent Ultrasnd - Exercise of Options and Total Voting Rights
08/10/2024 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241008:nRSH2480Ha&default-theme=true
RNS Number : 2480H Intelligent Ultrasound Group PLC 08 October 2024
8 October 2024
Intelligent Ultrasound Group plc
("Intelligent Ultrasound" or the "Group" or the "Company")
Exercise of share options and change to total voting rights
Intelligent Ultrasound Group plc (AIM: IUG), the ultrasound AI software and
simulation company, announces that it has issued, conditional on admission,
150,000 new ordinary shares of 1 pence each in the capital of the Company
("Ordinary Shares"), pursuant to the exercise of share options.
The new Ordinary Shares will rank pari passu with the existing Ordinary Shares
in issue and application has been made for the new Ordinary Shares to be
admitted to trading on the AIM Market of the London Stock Exchange
("Admission"). Admission is expected to occur, and dealings in the new
Ordinary Shares commence, at 8:00 a.m. on 11 October 2024.
Total Voting Rights
Following Admission, the Company will have 327,189,921 Ordinary Shares in
issue. This figure of 327,189,921 may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change of their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.
ENDS
For further information, please contact:
Intelligent Ultrasound Group plc www.intelligentultrasound.com (http://www.intelligentultrasound.com/)
Stuart Gall, CEO Tel: +44 (0)29 2075 6534
Helen Jones, CFO
Cavendish Capital Markets Limited
(Nominated adviser and broker)
Giles Balleny / Dan Hodkinson (Corporate Finance) Tel: +44 (0)20 7397 8900
Nigel Birks (Life Sciences Specialist Sales)
Dale Bellis (Sales)
TB Cardew - PR Advisors Intelligentultrasound@tbcardew.com (mailto:Intelligentultrasound@tbcardew.com)
Ed Orlebar Tel: +44 (0)7738 724630
Allison Connolly Tel: +44 (0)7587 453955
Emma Pascoe-Watson Tel: +44 (0)7774 620415
Jessica Pilling Tel: +44 (0)7918 584573
About Intelligent Ultrasound Group
Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to
clinic' ultrasound companies, specialising in real-time hi-fidelity virtual
reality simulation for the ultrasound training market ('classroom') and
artificial intelligence-based clinical image analysis software tools for the
diagnostic medical ultrasound market ('clinic'). Based in Cardiff in
the UK and Atlanta in the US, the Group has two revenue streams:
Simulation
Real-time hi-fidelity ultrasound education and training through simulation.
Our main products are the ScanTrainer obstetrics and gynaecology training
simulator, the HeartWorks echocardiography training simulator,
the BodyWorks Eve Point of Care and Emergency Medicine training simulator
with Covid-19 module and the new BabyWorks Neonate and Paediatric training
simulator. To date over 1,700 simulators have been sold to over 800 medical
institutions around the world.
Clinical AI software
Deep learning-based algorithms to make ultrasound machines smarter and more
accessible using our proprietary ScanNav ultrasound image analysis
technology. Current products on the market utilising this technology are GE
HealthCare's SonoLyst software that is incorporated in their Voluson Expert
and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies
ultrasound-guided needling by providing the user with real-time AI-based
anatomy highlighting for a range of medical procedures; and NeedleTrainer
that teaches real-time ultrasound-guided needling and incorporates ScanNav
Anatomy PNB.
www.intelligentultrasound.com (http://www.intelligentultrasound.com/)
NOTE: ScanNav Anatomy PNB is CE approved and cleared for sale in the US by the
FDA but is not available for sale in any other territory requiring government
approval for this type of product.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END IOEFLFFRIDLDIIS